EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases

Joseph L Dempsey, George N Ioannou, Rotonya M Carr

Seminars in Liver Disease · 01.11.2023 · 43 (04) · 367-382

DOI: 10.1055/a-2186-3557 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.11.2023. Verfasst von Joseph L Dempsey und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, School of Medicine, University of Washington, Seattle, Washington. Hauptthemen laut MEDLINE: Fatty Liver, Liver Diseases, Alcoholic, Hepatitis C, Chronic. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 195 Literaturangaben. Gefördert von: National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Alcohol Abuse and Alcoholism.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The steatotic diseases of metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and chronic hepatitis C (HCV) account for the majority of liver disease prevalence, morbidity, and mortality worldwide. While these diseases have distinct pathogenic and clinical features, dysregulated lipid droplet (LD) organelle biology represents a convergence of pathogenesis in all three. With increasing understanding of hepatocyte LD biology, we now understand the roles of LD proteins involved in these diseases but also how genetics modulate LD biology to either exacerbate or protect against the phenotypes associated with steatotic liver diseases. Here, we review the history of the LD organelle and its biogenesis and catabolism. We also review how this organelle is critical not only for the steatotic phenotype of liver diseases but also for their advanced phenotypes. Finally, we summarize the latest attempts and challenges of leveraging LD biology for therapeutic gain in steatotic diseases. In conclusion, the study of dysregulated LD biology may lead to novel therapeutics for the prevention of disease progression in the highly prevalent steatotic liver diseases of MASLD, ALD, and HCV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverLiver Diseases, AlcoholicHepatitis C, ChronicHumansLipid Droplets

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, School of Medicine, University of Washington, Seattle, Washington.
  • Division of Gastroenterology, Veterans Affairs Puget Sound Healthcare System Seattle, Washington.

Förderung

  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute on Alcohol Abuse and Alcoholism

Zitieren

APA

Dempsey, J. L., Ioannou, G. N., & Carr, R. M. (2023). Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases. Seminars in Liver Disease, 43(04), 367-382. https://doi.org/10.1055/a-2186-3557

Vancouver

Dempsey JL, Ioannou GN, Carr RM. Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases. Seminars in Liver Disease. 2023;43(04):367-382. doi:10.1055/a-2186-3557

BibTeX
@article{Dempsey2023,
  author = {Dempsey, Joseph L and Ioannou, George N and Carr, Rotonya M},
  title = {Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases},
  journal = {Seminars in Liver Disease},
  year = {2023},
  volume = {43},
  number = {04},
  pages = {367--382},
  doi = {10.1055/a-2186-3557}
}
Kostenlos starten →